Histological review in the primary analysis of the trial material classified 58 out of 59 samples included in this study as GBM grade 4, and one sample was classified as astrocytoma grade 3, but all samples were IDH1 mutation-negative. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).